{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7"},{"groupId":"OG001","value":"9.5"},{"groupId":"OG002","value":"5.0"}]}],"title":"Wk 8 (n=93,84,60)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"},{"groupId":"OG001","value":"21.5"},{"groupId":"OG002","value":"16.1"}]}],"title":"Wk 24 (n=83,79,56)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6"},{"groupId":"OG001","value":"30.8"},{"groupId":"OG002","value":"23.3"}]}],"title":"Wk 48 (n=85,78,60)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"84"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"Percentage of participants who were RF seropositive at BL who became RF seronegative over the course of the study. RF seropositive status was defined as RF ≥ 20 international units (IU) per mL. RF seronegative status was defined as RF \\< 20 IU/mL.","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"NUMBER","populationDescription":"RF seropositive participants from the ITT-M2 population, n=number of participants assessed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"BL, Weeks 8, 24, and 48","title":"Percentage of Participants Who Were Rheumatoid Factor (RF) - Seronegative","type":"SECONDARY","unitOfMeasure":"percentage of participants"}